Instead, we hypothesised that MCP‐1 expression may drop in late and advanced late‐stage triple negative breast cancers that had already gained metastatic potential and, therefore, sought to reconsider our findings in the context of breast cancer stages. This evidence concerns the gene CCL2 and breast carcinoma.